Autologous peripheral blood-derived CD34+ cells

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Autologous peripheral blood-derived CD34+ cells
DrugBank Accession Number
DB16367
Background

Autologous peripheral blood-derived CD34+ cells, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells.1 It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage).

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Cell transplant therapies
Other cell transplant therapies
Synonyms
  • CD34+ Cells
  • CLBS119
External IDs
  • Autologous peripheral blood-derived CD34+ cells

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Autologous peripheral blood-derived CD34+ cells have potential tissue repair ability in part due to its anti-inflammatory function which were demonstrated in pre-clinical models, including one of lung inflammation.1 Due to the pre-programmed tissue repair effects mediated by anti-inflammatory and pro-angiogenic functions of these cells, this cell therapy is currently being investigated against COVID-19-induced lung damage in recovered adult patients that still are experiencing hypoxia and require supplemental oxygen.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Libmeldy6000000 cells/mLIntravenousOrchard Therapeutics (Netherlands) Bv2021-02-11Not applicableEU flag
Strimvells5000000 cells/mlIntravenousOrchard Therapeutics (Netherlands) Bv2020-12-20Not applicableEU flag
Zynteglo10600000 cells/mLIntravenousBluebird Bio (Netherlands) B.V.2021-01-12Not applicableEU flag

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Caladrius Biosciences: CLBS119 [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatment(Advanced) Coronary Heart Disease / Chronic Myocardial Ischemia / Refractory Angina Pectoris1
3TerminatedSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas1
2Active Not RecruitingTreatmentMyelodysplastic Syndrome (MDS) With Refractory Anemia (RA) / Severe Aplastic Anemia (SAA)1
2CompletedTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
2CompletedTreatmentMyocardial Ischemia1
2CompletedTreatmentPlasma Cell Myeloma1
2RecruitingTreatmentAtherosclerosis Obliterans / Buerger's Disease / Critical Limb Ischemia (CLI) / Thromboangiitis Obliterans1
2RecruitingTreatmentCoronary Microvascular Disease / Coronary Microvascular Dysfunction / Microvascular coronary artery disease1
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2, 3CompletedTreatmentCritical Limb Ischemia (CLI)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 18, 2020 16:55 / Updated on March 03, 2021 21:58